Source:http://linkedlifedata.com/resource/umls/id/C0879262
NCI: A drug that is being studied for its ability to enhance the effectiveness of fluorouracil and prevent gastrointestinal side effects caused by fluorouracil. It belongs to the family of drugs called antimetabolites.,CHV: a kind of cancer treatment drug,CHV: a kind of cancer treatment drug,PDQ: An oral fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-flurouracil (5-FU) activity, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, thereby inhibiting DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. CDHP is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyltransferase (the major enzyme